Breast Cancer Risk Hormones Young Onset
Hormone Therapy and Young-Onset Breast Cancer: A Complex Relationship unveiled
Table of Contents
- Hormone Therapy and Young-Onset Breast Cancer: A Complex Relationship unveiled
New Research Sheds Light on Hormone Replacement Therapy’s Impact on Premature Breast Cancer
London, UK – A comprehensive study published in The Lancet Oncology has investigated the intricate relationship between hormone therapy (HT) use and the risk of developing young-onset breast cancer, offering nuanced insights that could inform clinical practice. The findings, based on a median follow-up of 7.8 years,suggest that while overall HT use may not be linked to an increased risk,specific types of hormone therapy exhibit differing associations.
Estrogen-Only Therapy Linked to Reduced Risk, Estrogen-Plus-Progestogen Shows Trend Towards Increased Risk
The study revealed that the use of estrogen-only hormone therapy (E-HT) was associated with a significantly reduced risk of young-onset breast cancer. Conversely, estrogen-plus-progestogen hormone therapy (EP-HT) showed a trend toward an increased risk.These associations were observed after adjusting for various covariates.
Specifically, E-HT was linked to a hazard ratio (HR) of 0.86, indicating a protective effect. This translated to a risk difference of -0.5% compared to non-users, whose estimated cumulative risk was 4.1%.In contrast, EP-HT had an HR of 1.10, suggesting a potential increase in risk.
Key Subgroup Findings Highlight Nuances in E-HT and EP-HT Effects
The protective effect of E-HT was particularly pronounced in specific subgroups:
Long-term users (more than 2 years): HR of 0.80
Earlier initiators (started before 45 years of age): HR of 0.77
Former users: HR of 0.77
These findings suggest that the duration and timing of E-HT initiation, as well as cessation of use, may play a role in its association with breast cancer risk.
On the other hand, EP-HT demonstrated a significant correlation with an increased risk of young-onset breast cancer among:
Long-term users: HR of 1.18
Current users: HR of 1.21
Those who had not undergone gynecologic surgery: HR of 1.15
These results underscore the importance of considering the specific formulation and usage patterns of HT when evaluating breast cancer risk.
Implications for Clinical Recommendations and Future Research
The investigators noted that a substantial proportion of E-HT users in their pooled sample had also undergone hysterectomy (with or without bilateral oophorectomy). This observation supports the notion that exogenous estrogen replacement for depleted endogenous estrogen may offer health benefits, at least concerning breast cancer risk.Christelle Lévy, writing in a linked commentary, emphasized the novelty of these findings and their potential to shape clinical recommendations for women with young-onset breast cancer. However, she also highlighted critical considerations before widespread implementation.
Addressing Gaps and Future Directions
Lévy pointed out that other risks, such as endometrial cancer, must be carefully weighed, particularly for young women with a preserved uterus. In such cases, an estrogen-plus-progestogen combination might be preferred due to the gynecological risk profile.A significant limitation identified by both the researchers and the commentator was the absence of data on BRCA status.Lévy stressed that hormonal treatment could potentially promote cellular changes in women at high risk of breast cancer, including those with precancerous lesions, making BRCA status a crucial factor for future research.
Despite these caveats, the commentator concluded that the data are encouraging and can assist physicians in discussions with young women requiring estrogen supplementation, often prescribed for premature ovarian deficiency, which is itself linked to an increased risk of chronic illness.
This research provides valuable insights into the complex interplay between hormone therapy and young-onset breast cancer, paving the way for more personalized and evidence-based clinical guidance.
**
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2025 Springer Healthcare Ltd, part of Springer Nature*